Cart
0
Hegseth Announces To Screen Troops Over 30 for Low Testosterone
Defense Secretary Pete Hegseth has announced a new Department of Defense initiative requiring annual testosterone-deficiency screenings for service members aged 30 and older. The program, which officials say is designed to improve military readiness and long-term health, has sparked discussion over performance, preventive medicine, and how the policy fits into the Pentagon's broader healthcare priorities.
U.S. Marine Corps photo by Cpl. Juaquin Greaves
The Pentagon is adding a new annual health check for thousands of U.S. troops.
This time, it's focused on testosterone.
Gear Spotlight- What Our Readers Are Picking Up
On July 17, 2026, Defense Secretary Pete Hegseth announced that the Department of Defense will begin annual testosterone-deficiency screenings for all active-duty service members aged 30 and older. Troops under 30 will be allowed to participate voluntarily.
Hegseth unveiled the policy in a video posted on social media, describing it as another step toward improving military readiness.
"I'm authorizing a new screening program for testosterone deficiency for our service members, ensuring you have the right testosterone levels to operate at your absolute best," he said.
According to the Pentagon, the screening will become part of each service member's routine Periodic Health Assessment, the annual medical evaluation already required across the armed forces.
If you've followed this far, here's why the policy exists.
Testosterone naturally declines with age, beginning gradually in many men during their 30s.
While some experience little change, others develop testosterone deficiency, also known as hypogonadism, which can lead to persistent fatigue, reduced muscle mass, slower recovery, lower bone density, decreased endurance, difficulty concentrating, depression, and reduced libido.
For military personnel whose jobs demand physical strength, mental focus, and rapid decision-making, defense officials argue that identifying medically significant hormone deficiencies early could improve overall readiness.
The Pentagon emphasized that the program is voluntary when it comes to treatment.
A low test result will not automatically lead to medication.
Instead, physicians will conduct additional evaluations to determine whether the individual has a genuine medical deficiency. Doctors may order repeat blood tests, review medical history, assess symptoms, and investigate other possible causes before recommending treatment.
If diagnosed, eligible service members may be offered Testosterone Replacement Therapy (TRT) or other medically appropriate options intended to restore hormone levels to the normal physiological range.
Military officials say the goal is restoration, not enhancement.
The policy is not intended to provide performance-enhancing hormone use beyond normal medical standards.
The announcement also comes amid broader changes to Pentagon healthcare policy.
Since returning to office, the Trump administration has prohibited federal funding for most forms of gender-affirming hormone therapy for transgender service members, describing such treatments as inconsistent with military policy. Hegseth's announcement did not address how the testosterone screening program applies to the more than 231,000 women serving on active duty, nor did it announce a comparable hormone-screening initiative for female service members.
Supporters of the policy argue it reflects preventive medicine.
Some military physicians and veterans have said undiagnosed hormone deficiencies can negatively affect operational performance, recovery after strenuous training, and long-term health. They view routine screening as comparable to monitoring blood pressure, cholesterol, or other medical conditions that could affect deployment readiness.
Others urge caution.
The Endocrine Society and other medical organizations recommend diagnosing testosterone deficiency only when both clinical symptoms and repeated laboratory testing confirm the condition. Medical experts also note that testosterone therapy carries potential risks, including increased red blood cell counts, fertility reduction, acne, sleep apnea complications, and the need for ongoing medical monitoring.
Questions also remain about implementation.
The Department of Defense has not yet released detailed guidance explaining how abnormal results could affect deployment status, fitness evaluations, or retention decisions. Officials say additional clinical protocols are expected before the program is fully implemented.
The screenings are expected to begin during upcoming annual health assessments across the military.
Whether the initiative becomes a permanent part of military medicine will likely depend on its impact on troop health, readiness, and long-term clinical outcomes.
Editor's Note
The Department of Defense has announced the screening program but has not yet released comprehensive implementation guidance. Medical treatment will remain voluntary and subject to physician evaluation, and additional policy details are expected before full rollout.
